2,492
Views
4
CrossRef citations to date
0
Altmetric
Coronaviruses

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, & ORCID Icon show all
Pages 2315-2325 | Received 24 May 2022, Accepted 21 Aug 2022, Published online: 27 Sep 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Eloy E. Ordaya & Raymund R. Razonable. (2024) Emerging anti-spike monoclonal antibodies against SARS-CoV-2. Expert Opinion on Biological Therapy 24:3, pages 191-201.
Read now

Articles from other publishers (3)

Qin Yalan, Hao Lingfang, Liu Xisong, Liang Run, Zhang Junjing & Zhang’ An. (2024) Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study. BMC Pharmacology and Toxicology 25:1.
Crossref
Ji Yeon Lee, Seon Hee Bu, EunHyang Song, Seongcheol Cho, Sungbong Yu, Jungok Kim, Sungmin Kym, Kwang Won Seo, Ki Tae Kwon, Jin Yong Kim, Sunghyun Kim, Keumyoung Ahn, Nahyun Jung, Yeonmi Lee, Yoobin Jung, Chankyoung Hwang & Sang Won Park. (2023) Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea. Infectious Diseases and Therapy 12:10, pages 2417-2435.
Crossref
Mahali S. Morgan, Kexin Yan, Thuy T. Le, Ryan A. Johnston, Alberto A. Amarilla, David A. Muller, Christopher L. D. McMillan, Naphak Modhiran, Daniel Watterson, James R. Potter, Julian D.J. Sng, Mary Lor, Devina Paramitha, Ariel Isaacs, Alexander A. Khromykh, Roy A. Hall, Andreas Suhrbier, Daniel J. Rawle & Jody Hobson-Peters. (2022) Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern. Viruses 15:1, pages 139.
Crossref